The Treatment of Oestrogen-Escaped Carcionoma of the Prostate with Estramustine Phosphate

Chisholm, G. D.; O'donogue, E. P. N.; Kennedy, Cornelis

doi:10.1111/j.1464-410x.1977.tb04559.x

Cited by 28 publications

(8 citation statements)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although estramustine was not administered alone in this study, these data appear superior to those previously reported for hormoneresistant groups (Table 1). [26][27][28][29][30][31] The response rate of 70 percent in patients with stage D disease and no previous therapy is consistent with the results reported by others administering estramustine alone. 26.28.31-33 Clinical studies currently are in progress by the National Prostate Cancer Project to determine the efficacy of estramustine as an adjuvant to definitive surgery or radiotherapy in patients with newly diagnosed nonmetastatic cancer of the prostate."?"…”

Section: Clinical Studiessupporting

confidence: 81%

Estramustine Phosphate Sodium

Hauser¹,

Merryman²

1984

Drug Intelligence & Clinical Pharmacy

View full text Add to dashboard Cite

Estramustine phosphate is approved by the Food and Drug Administration for oral use in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a conjugate of 17 beta-estradiol and the carbamate of nitrogen mustard. Although its therapeutic efficacy has been demonstrated, it is not clear to what extent each constituent contributes to estramustine's effectiveness. Estramustine phosphate therapy achieves objective response rates of 60-90 percent in advanced stage D prostatic cancer patients with no prior hormonal therapy. These results are consistent with those obtained with conventional hormonal therapy in similar patient populations. Therapeutic efficacy does not appear to increase when estramustine is used concurrently with other cytotoxic chemotherapeutic agents. An objective response rate of 20-30 percent can be anticipated in patients refractory to conventional hormonal therapy. It is in this group, the estrogen-resistant patients, that estramustine shows the most promise. Adverse effects of estramustine are similar to those of diethylstilbestrol. Gastrointestinal and cardiovascular side effects appear to be the most important and may be severe enough to require discontinuation of therapy.

show abstract

Section: Clinical Studiessupporting

confidence: 81%

Estramustine Phosphate Sodium

Hauser¹,

Merryman²

1984

Drug Intelligence & Clinical Pharmacy

View full text Add to dashboard Cite

show abstract

“…Although used widely, the efficacy of estramustine (Estracyt) has never been proven in controlled clinical trials. Subjective response rates of up to 35% have been reported (Leistenschneider and Nager, 1989;Chisholm et al, 1977), but this may be no better than second-line hormone therapy at the cost of greater toxicity (Johansen et al, 1991). Fracture of long bones is a common problem in patients with extensive bony disease.…”

Section: Symptomatic Relapsementioning

confidence: 99%

The Management of Carcinoma of the Prostate after Failed Primary Therapy

Howard

1993

British Journal of Urology

View full text Add to dashboard Cite

“…Also estramustine phosphate represents a high-dose estrogen treatment and acts probably also as a cytostatic agent. The drug has been shown to relieve pain and to improve the general condition in prostate cancer patients who progress on ongoing primary hormone manipula tions [21,22], According to the present study with admittedly few patients within each group, secondary hormone treatment with 1 of the above 3 hormonal agents reduces elevated PSA levels by > 50% in 20-30% of the patients with hor mone-resistant prostate cancer. These biochemical re sponses objectively indicate that at least some of the tumor cells are still sensitive for endocrine manipulation.…”

Section: Treatmentmentioning

confidence: 99%